
United States · Mental health care startup
Osmind is a San Francisco-based Public Benefit Corporation founded in 2020.
Funding reportedLast round: Series B
Osmind is a San Francisco-based Public Benefit Corporation founded in 2020.
The company specializes in an electronic health record (EHR) and mental health operating platform designed for clinicians and researchers focused on advancing innovative mental health treatments. Osmind's mission is to enhance precision psychiatry by streamlining clinical workflows and aggregating real-world data to support evidence-based medicine for patients with moderate to severe mental health conditions. The platform offers a range of features tailored for interventional psychiatric workflows, including clinical EHR, outcome tracking, patient engagement tools, reimbursement support, data analytics, and journaling tools. Osmind serves over 400 clinics across 45 U.S. states, primarily targeting mental health clinicians, researchers, specialized treatment providers, pharmaceutical companies, and health insurers. The company is backed by prominent investors and is committed to improving access to effective treatments for all backgrounds.
Funding, as reported
From Osmind's own website: 28 on the team.
And 10 more on the team.
AdvisersMedical Advisor
What they build
Known for
innovative treatmentspsychiatry clinical researchhealth carepsychiatry ehrresearch and development toolspsychiatry research data platformketamine treatmentpractice growthhipaa compliancepsychiatry treatment optimizationpsychiatric billingtreatment-resistant depressionpractice automation toolse-prescribingpsychiatry treatment efficacyinsurance reimbursement
Built with from their website
GitHub ActionsAmazon SESGoogle Tag ManagerAmazon CloudFrontdbtAWS Trusted AdvisorLeverGoogle AdsChameleonClarity SDM
Google WorkspaceCloudFlareGemAkamai Connected CloudViewport MetaNextGen RCMLovableAmazon Simple Email Service
Add your raise, your deck and your story, and put Osmind in front of investors. Or tell us what we have wrong.